Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 107

Results For "mg"

1151 News Found

Caplin Steriles gets US FDA approval for blood pressure injection
News | September 08, 2021

Caplin Steriles gets US FDA approval for blood pressure injection

Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.


Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA
Drug Approval | September 06, 2021

Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA

Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)


DGCI approves Hetero’s Tocilizumab
Drug Approval | September 06, 2021

DGCI approves Hetero’s Tocilizumab

Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month


Accutest enables NMPA approval for Qilu’s Abiraterone
Drug Approval | September 06, 2021

Accutest enables NMPA approval for Qilu’s Abiraterone

The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India


Natco Pharma launch Nat-Lenalidomide in Canada
Drug Approval | September 02, 2021

Natco Pharma launch Nat-Lenalidomide in Canada

Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)


Reddy-Lenalidomide launched in Canada
Drug Approval | September 02, 2021

Reddy-Lenalidomide launched in Canada

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market


Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
Drug Approval | September 01, 2021

Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab

JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis


SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate
Drug Approval | September 01, 2021

SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate

Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine


Dr. Reddy's announce launch two drugs in the US market
News | August 31, 2021

Dr. Reddy's announce launch two drugs in the US market

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100


US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
Drug Approval | August 31, 2021

US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723

The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers